Antifibrinolytic therapy was used in 1,114 patients who had aneurysmal subarachnoid hemorrhage (SAH) and who were treated by the 13 institutions of the Cooperative Aneurysm Study. Patients were started on treatment within one week after SAH was diagnosed, and therapy was discontinued 14 days after the ictus. Rebleeding occurred in 10% of the treated patients. Overall mortality among the treated patients during the two weeks following hemorrhage was 10.7%. Though some minor and a few major side effects occurred, serious complications of therapy were infrequent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archneur.1981.00510010051009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Idiopathic non-mast cell angioedema: Treatment insights from global experts.
Allergy Asthma Proc
January 2025
From the Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California and.
Idiopathic non-mast cell angioedema (INMA) is a rare disease typified by recurrent attacks of cutaneous and subcutaneous swelling. Every attack carries the potential for severe morbidity and, in the case of laryngeal involvement, mortality. Whereas therapies approved for hereditary angioedema (HAE) have been used in the care of patients with INMA, little is known with regard to their efficacy for the treatment of this disease.
View Article and Find Full Text PDFTotal hip arthroplasty was found to be safe in Jehovah's Witness patients: a multi-centered matched study.
Arch Orthop Trauma Surg
December 2024
Duke University Health System, Durham, USA.
Background: Jehovah's Witness patients refuse blood transfusion because of their religious beliefs making total hip arthroplasty (THA) challenging. This study aims to determine the safety of THA in Jehovah's Witness patients using standard perioperative protocols as well as evaluate the effectiveness of tranexamic acid (TXA) in controlling blood loss.
Methods: Databases from two tertiary academic centers were queried from 2003 to 2021 to identify THA patients.
Use of Tranexamic Acid in SARS-COV-2: Boon or Bane?
Arch Razi Inst
June 2024
Department of Community and Family Medicine, AIIMS Bibinagar, Hyderabad, Telangana-508126.
The devastating pandemic of SARS-CoV-2 (COVID-19) began in Wuhan, China, and spread rapidly through most parts of the world in the second half of 2020. The air droplet spread of SARS-CoV-2 is of great global health concern as it is potentially fatal. Various drugs and treatment modalities have been tried to date, but none have been found to be definitive.
View Article and Find Full Text PDFPreoperative D-dimer level predicts adverse events after coronary endarterectomy combined with coronary artery bypass grafting: a retrospective cohort study.
J Cardiothorac Surg
December 2024
Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beilishi Road No. 167, Xicheng District, Beijing, 100037, China.
Background: Little is known about the role of D-dimer (DD) on the prognosis of patients undergoing coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG).
Methods: A total of 371 patients undergoing CE with CABG between January 2018 and July 2022 were retrospectively enrolled. The primary endpoint was the perioperative major adverse cardiovascular and cerebrovascular events (MACCE).
The optimal dose of intravenous tranexamic acid for reducing blood loss in spinal surgery: a network meta-analysis.
BMC Musculoskelet Disord
December 2024
Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Background: This study aims to evaluate the optimal dose of intravenous tranexamic acid (TXA) for reducing blood loss in spinal surgery.
Methods: A systematic search was conducted in the PubMed, Embase, Cochrane Library database from inception until November 2023. Randomized controlled trials (RCTs) incorporating diverse TXA dosing regimens for spinal surgery were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!